#Cambridge #United Kingdom #AI-driven #Skin Health #Sequential

Sequential’s Latest Funding Boosts AI Innovation in Skin Health

In a significant milestone, Sequential, a forefront leader in non-invasive genomic testing from human clinical samples, has officially closed its first funding round, securing $3.5 million. This funding marks a critical step in advancing their mission to create an AI-powered discovery platform that focuses on next-generation skin health ingredients and multi-omics testing.

The funding round saw strategic participation from notable venture firms, including Sparkfood and Corundum Systems Biology (CSB), alongside contributions from Dermazone Holdings, SOSV, and Scrum Ventures. This initial round brings the total funding raised by Sequential to $7.5 million when accounting for both dilutive and non-dilutive sources of capital.

The Innovation Behind Sequential

Sequential is not just another biotech company; it is pioneering the evaluation of how biotechnological and pharmaceutical products impact microbial and host biomarkers through its unique non-invasive testing platform. This innovative approach aims to transform complex biological data into actionable insights, paving the way for credible and effective product development.

As Sequential dives deeper into the skin health industry, they have amassed one of the most extensive clinical datasets, featuring over 50,000 samples, 4,000 ingredients, and 10,000 participants worldwide. The freshly obtained funding will primarily support the development of an AI-driven discovery engine, which aims to leverage this rich dataset for predicting, optimizing, and discovering new bioactive ingredients and active complexes.

Quotes from the Leadership

Dr. Oliver Worsley, CEO and co-founder of Sequential, shared his vision, stating, “Our mission is to bring pharmaceutical-grade evidence and computational accuracy to personal care. By applying AI to one of the largest clinical datasets in dermatological health, we can uncover new skin biomarkers and systematically design and validate revolutionary ingredient combinations. This investment enables us to realize this vision.”

Anouk Veber, a leader from Sparkfood, expressed confidence in Sequential’s approach, noting, “Sequential has uniquely bridged biology, clinical validation, and consumer product development, connecting molecular and microbial biomarkers to product performance in real-world settings. We believe their AI-based platform will reshape the way next-generation personal care products are developed and distinguished.”

Hidehiko Otake, CEO of Corundum Systems Biology, echoed this sentiment, emphasizing their alignment in transforming human health through the power of large datasets, microbiome insights, and artificial intelligence. He confirmed, “Our ongoing support during this cycle reflects our belief in their vision and our shared commitment to redefine the future of personal care.”

The Path Ahead for Sequential

With their robust combination of systems biology, clinical research infrastructure, and advanced computational modeling, Sequential is set to establish a new standard for data-driven innovation in personal care and adjacent health categories. The company aims to further develop its biomarker discovery programs and global partnerships while constructing a scalable discovery engine designed for unlocking the next generation of scientifically validated complexes.

In conclusion, Sequential's groundbreaking work not only stands to impact the beauty and skincare industries profoundly but also sets a precedent for how biotechnology companies can utilize large datasets and modern technology to innovate and better human health. With rising interest and investment in AI technology, Sequential is poised to lead this evolution in dermatological science and skincare solutions.